Topic resource collection
Approved comparison material connected to this topic.
5 resourcesRead both sides
Thymosin Alpha-1 TLR activation on dendritic cells, shifts cytokine profile toward IL-10, enhances thymic T-cell output 1.6–3.2mg subcutaneous Twice weekly 12–16 weeks First-line choice for immune reconstitution in PTLDS. Address…
Thymosin Alpha-1 Treg restoration, IL-6/TNF-alpha reduction 1.6 mg SC twice weekly × 8–12 weeks Phase III trial data in viral/autoimmune conditions; no Lyme-specific RCTs Strongest mechanistic rationale for immune recalibration i…
Thymalin T-cell maturation, Treg restoration Immune dysregulation, T-cell exhaustion Clinical use in Russia/Eastern Europe; limited Western trials 10mg SubQ every 48 hours × 10 doses Strongest immunomodulatory data for post-infec…
Peptide efficacy for Lyme support depends on which immune dysfunction you're addressing—T-cell exhaustion, inflammatory cytokine dominance, NK cell suppression, or residual antimicrobial activity. Here's how the primary candidate…
Researchers investigating peptides for Lyme disease support are exploring multiple compounds with distinct mechanisms targeting immune dysregulation, neuroinflammation, and mitochondrial dysfunction—three core pathways implicated…